We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellular bubbles used to deliver Parkinson's meds directly to brain
News

Cellular bubbles used to deliver Parkinson's meds directly to brain

Cellular bubbles used to deliver Parkinson's meds directly to brain
News

Cellular bubbles used to deliver Parkinson's meds directly to brain

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellular bubbles used to deliver Parkinson's meds directly to brain"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Researchers at the University of North Carolina (UNC) at Chapel Hill have used exosomes -- tiny bubbles of protein and fat produced naturally by cells -- to bypass the body's defenses and deliver a potent antioxidant directly to the brain to treat Parkinson's disease.


And what's the best way of getting her drug-packed exosomes to the brain? It looks like a simple nasal spray will do the trick, say Elena Batrakova and her colleagues at the UNC Eshelman School of Pharmacy's Center for Nanotechnology in Drug Delivery.


Batrakova and her colleagues extracted exosomes from immune cells and successfully loaded them with the enzyme catalase, a potent antioxidant that counters the neuron-killing inflammation responsible for Parkinson's and other degenerative neurological disorders. Their work was published in the Journal of Controlled Release.


This is the first time a large therapeutic protein like catalase has been delivered to the brain using exosomes. Getting drugs into the brain is extremely difficult in general because it is protected and isolated from the rest of the body by the blood-brain barrier, which is extremely selective about what is allowed to pass through.


Batrakova and her team at the pharmacy school harvested exosomes from macrophages, white blood cells that are responsible for clearing foreign material from the body. Exosomes are tiny spheres produced by cells to carry chemical messages. They are made of the same material that makes up cell membranes. Diseases like cancer and AIDS propagate throughout the body by hijacking exosomes.


"Exosomes are engineered by nature to be the perfect delivery vehicles for proteins and genetic material," Batrakova says. "Catalase is a huge protein, and it is almost impossible to deliver across the blood-brain barrier alone. We use exosomes from white blood cells, which are invisible to the immune system and easily interact and fuse with the blood-brain barrier to deliver their cargo across it."


Catalase counteracts the effects of free radicals, destructive molecules that are byproducts of cellular activity and especially prevalent in areas of chronic inflammation.


"Catalase is one of the most potent antioxidants in nature," Batrakova says. "One molecule of catalase can deactivate about one million free radicals per second, and it never stops because the enzyme is not consumed in the reaction. No small molecule drug even comes close to matching it in speed or efficiency."


Traditional drugs -- from cold medicine to chemotherapy -- are composed of small molecules of a few dozen atoms, typically. Biopharmaceuticals, or biologics, are proteins produced by living cells. Proteins such as catalase are tens of thousands of times larger than the small molecules that make up traditional drugs.


Batrakova's goal is to develop personalized treatments by loading proteins into exosomes that have been extracted from a patient's own white blood cells. These packages of medicine will be ignored by the patient's immune system, which works against unknown proteins as well as many synthetic delivery vehicles.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

University of North Carolina at Chapel Hill


Publication

Matthew J. Haney, Natalia L. Klyachko, Yuling Zhao, Richa Gupta, Evgeniya G. Plotnikova, Zhijian He, Tejash Patel, Aleksandr Piroyan, Marina Sokolsky, Alexander V. Kabanov, Elena V. Batrakova. Exosomes as drug delivery vehicles for Parkinson's disease therapy.   Journal of Controlled Release, Published June 10 2015. doi: 10.1016/j.jconrel.2015.03.033


Advertisement